BACKGROUND Pneumococcal vaccine provides protection against invasive pneumococcal disease in population at risk. This study was conducted to compare the antibody response to 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in patients with thalassemia major. METHODS A randomized cross-over clinical trial was performed on 50 asplenic patients with thal...

Organization, 2003). Efforts to limit pneumococcal disease have focused primarily on antibiotic intervention and vaccination. However, after initial, and often dramatic, successes the effectiveness of these measures has consistently been overcome by the extremely adaptable and resilient pneumococcus. S. pneumoniae is naturally competent and readily incorporates DNA fragments derived from pneumo...

In the United States, influenza and pneumococcal diseases together are responsible for 20 to 50 times more deaths due to vaccine-preventable diseases than are all other vaccine-preventable diseases combined. During the 1990s, for example, it was estimated that more than 600,000 individuals died of influenza and pneumococcal diseases, whereas fewer than 15,000 deaths were reported for all other ...

The number of notified cases of invasive pneumococcal disease (IPD) in the 1st quarter of 2016 was substantially fewer than the previous quarter and marginally less than the number of notified cases in the 1st quarter of 2015. Overall, the decline in disease due to the serotypes targeted by the 13-valent pneumococcal conjugate vaccine (13vPCV) has been maintained across all age groups since the...

Pneumococcal conjugate vaccines (PCVs) have been successful in preventing invasive pneumococcal disease but effectiveness has been challenged by replacement of vaccine serotypes with non-vaccine serotypes. Vaccines targeting common pneumococcal protein(s) found in most/all pneumococci may overcome this limitation. This phase II study assessed safety and immunogenicity of a new protein-based pne...

CONTEXT Pneumococcal conjugate bacterial vaccines that are able to prevent invasive disease and mucosal infections have been developed. OBJECTIVE A meta-analysis of published data from trials on pneumococcal conjugate vaccine was performed to determine the efficacy in reducing the incidence of invasive disease caused by Streptococcus pneumoniae, pneumonia, and acute otitis media in healthy in...

BACKGROUND 10-valent conjugate pneumococcal vaccine/PCV10 was introduced in the Brazilian National Immunization Program along the year of 2010. We assessed the direct effectiveness of PCV10 vaccination in preventing nasopharyngeal/NP pneumococcal carriage in infants. METHODS A cross-sectional population-based household survey was conducted in Goiania Brazil, from December/2010-February/2011 t...

The number of notified cases of invasive pneumococcal disease (IPD) in the 2nd quarter of 2016 was substantially more than the previous quarter and marginally more than the number of notified cases in the 2nd quarter of 2015. Overall, the decline in disease due to the serotypes targeted by the 13-valent pneumococcal conjugate vaccine (13vPCV) has been maintained across all age groups, since the...

Applications of the heptavalent pneumococcal conjugate vaccine (PCV7) in the pediatric immunization schedule have dramatically reduced the incidence of pneumococcal diseases in both vaccinated children and unvaccinated individuals of all ages. However, increased infections caused by non-PCV7 serotypes have been reported by several groups. To overcome this problem, new vaccines covering more ser...